Wegovy Pill NZ: Medsafe Application, Cost and Release Date

Can you get the Wegovy pill in NZ? Not yet. Medsafe, New Zealand's medicines regulator, told 1News on 7 November 2026 that it has received an application for Wegovy oral tablets, the once-daily semaglutide pill from Novo Nordisk. It is still being assessed. There is no approval, no price and no Pharmac funding. It is the first GLP-1 weight-loss pill to reach Medsafe, and Medsafe said no other weight-loss drug is being considered for approval right now.

Here is what the application means, how long it could take, what it might cost and what you can use today.

Wegovy pill NZ: what we know so far

A reliance pathway lets Medsafe lean on the work of trusted overseas regulators to speed up its own review. 1News reported it can halve the usual target timeframes. Medsafe was clear that this is not a rubber stamp: it said it will check that the product "meets international standards for safety, quality and efficacy" before approving it.

When is the Wegovy pill coming to NZ?

Nobody can give a date yet. Seventy-five working days is about 15 weeks of business days, but Medsafe did not say when the clock started, and reviews pause while the company answers questions. Even after approval, Novo Nordisk decides when to supply it here.

The injection is a useful guide. Medsafe approved Wegovy injections in April 2025, but 1News reported at the time that it was "not yet available". Health NZ data reported by RNZ show people were being dispensed it from July 2025. A similar gap between approval and pharmacy shelves is possible for the tablet.

How much will the Wegovy pill cost in NZ?

There is no NZ price. Here is what is known:

• It will not be funded at launch. Pharmac's page, last updated 3 November 2026, says Wegovy and Mounjaro for weight loss are not funded, and it has not reported any application for the tablets.
• The injection is a private cost today. RNZ reported in November 2025 that Wegovy costs about $450 to $630 a month on prescription. 1News said some people pay around $600.
• Mounjaro costs more. RNZ reported in February 2026 that Mounjaro for weight loss ranges from about $430 to nearly $900 a month.
• US prices do not carry over. In the US the pill sells for US$149 to US$299 a month cash. NZ pricing is set separately. See our Wegovy pill cost guide for the US breakdown.

Is Wegovy funded by Pharmac?

Not yet, for weight loss. Pharmac's Obesity Treatment Advisory Group looked at the Wegovy injection in December 2025 and recommended funding it with a high priority for people with a high BMI and related health problems. It is now on Pharmac's Options for Investment List. In October 2026 a cardiovascular committee also signalled that it should be funded for some people with heart disease and a high BMI. If funding happens, Pharmac says prescribers would need to apply through Special Authority. Pharmac also says it "cannot say when, or if" it will be funded.

For type 2 diabetes, Pharmac lists dulaglutide (Trulicity) and liraglutide (Victoza) as funded for people who meet its criteria.

Wegovy pill vs injection

Both contain semaglutide. The pill needs a much bigger dose because only a small part of a tablet is absorbed.

Medsafe's NZ data sheet for the tablets does not exist yet. In the US, the label says to start at 1.5 mg and step up every 30 days to 25 mg. Your doctor sets your dose. Our Wegovy pill dosage chart shows the US schedule, and our GLP-1 pill vs shot guide goes deeper on which form suits whom.

Who would it be for?

Health NZ guidance for the Wegovy injection covers adults with a BMI of 30 or more, or 27 or more with at least one weight-related health problem. The tablet's NZ criteria will be set in its own data sheet if it is approved. Medical director Dr Prabani Wood told 1News a tablet is "more palatable" for people who do not like injecting, but added, "We don't have long-term evidence of effectiveness."

If you are pregnant, planning a pregnancy, under 18 or have had an eating disorder, talk to your doctor before any GLP-1 medicine.

Wegovy pill side effects

They are the same kind as the injection. In OASIS 4, stomach and gut effects such as nausea, diarrhoea, vomiting and constipation affected 74.0% of people on the pill and 42.2% on placebo. Most were mild to moderate and happened while the dose was going up. In the US the pill carries the same boxed warning as the injection about thyroid C-cell tumours seen in rodents.

Keep your muscle while you wait

Whether you start the injection now or wait for the tablet, appetite drops fast on semaglutide. Many people end up eating too little protein, and some of the weight lost can be muscle. Sharpy gives you one daily protein target, one 20-minute strength workout and a Shape Score, so you can see you are losing fat, not muscle. Our protein target guide explains how much you need.

What about Australia and Foundayo?

Across the Tasman, the TGA approved Wegovy tablets in early November 2026, and Novo Nordisk expects them in Australian pharmacies later in 2026. Our Wegovy pill Australia guide has the details. Eli Lilly's rival pill, Foundayo (orforglipron), is approved in the US. Medsafe said no other weight-loss drug is currently being considered, so it is not under review in NZ. See Wegovy pill vs Foundayo for how they compare.

The bottom line

The Wegovy pill is on its way through Medsafe, not on NZ shelves. Expect months, not weeks, then a private price at first. If you want to start now, the Wegovy injection is the approved semaglutide option, so talk to your GP. Either way, keep your protein up and your muscles working. Sharpy turns that into one simple plan a day.

Sources

• 1News: Medsafe weighs first application for GLP-1 weight-loss pill (7 November 2026)
• Pharmac: Wegovy and Mounjaro for weight loss not funded (updated 3 November 2026)
• RNZ: Wegovy an instant hit among both patients and doctors (November 2025)
• RNZ: Mounjaro now available for weight loss, but it comes with hefty price tag (23 February 2026)
• 1News: Weight loss drug Wegovy approved for use in NZ (2 April 2025)
• Wharton S et al. Oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). NEJM 2025
• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021